Samsung Biologics Announces Sunday-Monday July 19-20 an All-Cash Public Tender Offer to Acquire Swiss Peptide CDMO PolyPeptide Group for CHF 1.46 Billion ($1.8 Billion) at CHF 44.31 Per Share (40% Premium to the Undisturbed Share Price of CHF 31.65) — The Largest Biopharmaceutical M&A in South Korean History Anchored on Rising Client Demand for Peptide-Based GLP-1 Therapies in Obesity and Diabetes; PolyPeptide Board Unanimously Recommends the Offer and the Largest Shareholder Has Given an Irrevocable Tender Undertaking for Approximately 55.65% of Outstanding Shares
Samsung Biologics announced Sunday-Monday July 19-20, 2026 an all-cash public tender offer to acquire Switzerland's PolyPeptide Group for CHF 1.46 billion ($1.8 billion) at CHF 44.31 per share, a 40% premium to the undisturbed share price of CHF 31.65. The transaction represents the largest biopharmaceutical M&A in South Korean history. Strategic rationale: PolyPeptide is a global peptide contract development and manufacturing organization (CDMO) with accelerating revenue growth driven by rising client demand for peptide-based GLP-1 therapies for obesity and diabetes. The acquisition expands Samsung Biologics' capabilities beyond monoclonal antibody manufacturing (its historical strength) into peptide therapeutics and adds PolyPeptide's global network spanning Sweden, Belgium, France, the United States, and India, encompassing R&D, development, and commercial manufacturing capabilities. PolyPeptide's Board of Directors unanimously recommends the offer. The largest shareholder has given an irrevocable tender undertaking representing approximately 55.65% of outstanding shares. Samsung Biologics expects to complete the deal by end of 2026. The deal extends the July 2026 peptide-manufacturing consolidation wave alongside Novartis's $1.5 billion Myricx Bio acquisition (ADC payloads, July 6) and Lonza's Nona Biosciences TfR1 blood-brain-barrier deal (July 2).